Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer

Trial Profile

Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Sarcoma
  • Focus Therapeutic Use
  • Acronyms AtTEnd; AtTEnd/ENGOT-en7

Most Recent Events

  • 09 May 2025 Status changed from active, no longer recruiting to completed.
  • 11 Mar 2024 Planned primary completion date changed from 1 Nov 2023 to 1 Jan 2025.
  • 24 Oct 2023 Primary endpoint has been met. (PFS in the MSI [ Time Frame: Up to 18 months after the last patient enrolled ]) , according to Results presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top